Trial Profile
A study evaluating effect of CYP2C19 polymorphisms on the pharmacokinetics of BMS-823778
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2017
Price :
$35
*
At a glance
- Drugs BMS 823778 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- 01 Sep 2017 New trial record
- 29 Aug 2017 Results published in the British Journal of Clinical Pharmacology